5 results match your criteria: "Centre Hospitalier Universitaire Vaudois (CHUV) and Lausanne University[Affiliation]"
European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
J Thorac Oncol
September 2023
Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Article Synopsis
- Pleural mesothelioma (PM) is a serious cancer that is becoming more common in Europe, and understanding its epidemiology, treatment, and prognosis is crucial for improving patient outcomes.
- A study analyzed data from 2,766 PM patients across multiple European centers, revealing that most patients had the epithelioid subtype of PM and that many presented at advanced stages (III to IV) with poor overall survival rates averaging 17.4 months.
- Results indicated that treatment approaches, particularly multimodality treatments including surgery, notably improved survival chances, especially in patients who achieved a complete resection of the tumor.
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma.
Transl Lung Cancer Res
April 2021
Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Background: Targeted genetic profiling of tissue samples is paramount to detect druggable genetic aberrations in patients with non-squamous non-small cell lung cancer (NSCLC). Accurate upfront estimation of tumor cell content (TCC) is a crucial pre-analytical step for reliable testing and to avoid false-negative results. As of now, TCC is usually estimated on hematoxylin-eosin (H&E) stained tissue sections by a pathologist, a methodology that may be prone to substantial intra- and interobserver variability.
View Article and Find Full Text PDFImpact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network.
ESMO Open
April 2021
Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV) and Lausanne University, Lausanne, Switzerland.
Background: The COVID-19 pandemic has impacted all aspects of modern-day oncology, including how stakeholders communicate through social media. We surveyed oncology stakeholders in order to assess their attitudes pertaining to social media and how it has been affected during the pandemic.
Materials And Methods: A 40-item survey was distributed to stakeholders from 8 July to 22 July 2020 and was promoted through the European Society for Medical Oncology (ESMO) and the OncoAlert Network.
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy.
Ann Oncol
June 2020
Department of Medicine, Service of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; Vaccine and Immunotherapy Center, Centre Hospitalier Universitaire Vaudois (CHUV), Centre d'Immunothérapie et de Vaccinologie, Lausanne, Switzerland. Electronic address:
Patients with cancer and with preexisting active autoimmune diseases (ADs) have been excluded from immunotherapy clinical trials because of concerns for high susceptibility to the development of severe adverse events resulting from exacerbation of their preexisting ADs. However, a growing body of evidence indicates that immune-checkpoint inhibitors (ICIs) may be safe and effective in this patient population. However, baseline corticosteroids and other nonselective immunosuppressants appear to negatively impact drug efficacy, whereas retrospective and case report data suggest that use of specific immunosuppressants may not have the same consequences.
View Article and Find Full Text PDFSpatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.
J Thorac Oncol
November 2019
Translational Lung Research Center (TLRC) Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany; German Cancer Consortium (DKTK), Partner Site, Heidelberg, Germany. Electronic address:
Background: Tumor mutational burden (TMB) is an emerging biomarker used to identify patients who are more likely to benefit from immuno-oncology therapy. Aside from various unsettled technical aspects, biological variables such as tumor cell content and intratumor heterogeneity may play an important role in determining TMB.
Methods: TMB estimates were determined applying the TruSight Oncology 500 targeted sequencing panel.